Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANDA Sponsors Face Tight Controls On Meetings With US FDA After CR Letters

Executive Summary

Meetings are intended to help generic sponsors understand deficiencies, but agency won't let them run past 30 minutes.

You may also be interested in...



US FDA Appears To Have Avoided Shutdown-Related ANDA Bolus

Generic submissions were below historical norms in December and modestly higher January, meaning shutdown likely did not create a large pile of pending work.

ANDA Sponsors Need To 'Slow Down' And Focus On Quality, US FDA Generics Director Says

Kathleen Uhl says applicants can avoid RTRs by conducting quality checks before submission, but sponsors may have difficulty changing their approach because of how fundamental application speed is to their business model.

US FDA's Generics Program Reaches 'Steady State' Milestone

OGD Director Uhl says program is now in balance between the number of submissions and agency review actions.

Related Content

Topics

UsernamePublicRestriction

Register

PS124387

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel